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Abstract
Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-
defining diseases are increasingly seen in treated individuals. This is attributed to persistent virus expression in reservoirs and
to cell activation. Of note, in CD4
+ T cells and monocyte-macrophages of virologically-suppressed individuals, there is
continuedexpression ofmulti-splicedtranscriptsencodingHIVregulatoryproteins.Amongthem,Tatisessentialforvirusgene
expression and replication, either in primary infection or for virus reactivation during HAART, when Tat is expressed, released
extracellularly and exerts, on both the virus and the immune system, effects that contribute to disease maintenance. Here we
report results of an ad hoc exploratory interim analysis (up to 48 weeks) on 87 virologically-suppressed HAART-treated
individuals enrolled in a phase II randomized open-label multicentric clinical trial of therapeutic immunization with Tat (ISS T-
002). Eighty-eight virologically-suppressed HAART-treated individuals, enrolled in a parallel prospective observational study at
the same sites (ISS OBS T-002), served for intergroup comparison. Immunization with Tat was safe, induced durable immune
responses, and modified the pattern of CD4
+ and CD8
+ cellular activation (CD38 and HLA-DR) together with reduction of
biochemical activation markers and persistent increases of regulatory T cells. This was accompanied by a progressive
increment of CD4
+ T cells and B cells with reduction of CD8
+ T cells and NK cells, which were independent from the type of
antiretroviral regimen. Increase in central and effector memory and reduction in terminally-differentiated effector memory
CD4
+ and CD8
+ T cells were accompanied by increases of CD4
+ and CD8
+ T cell responses against Env and recall antigens. Of
note, more immune-compromised individuals experienced greater therapeutic effects. In contrast, these changes were
opposite, absent or partial in the OBS population. These findings support the use of Tat immunization to intensify HAART
efficacy and to restore immune homeostasis.
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Introduction
The use of antiretroviral drugs has changed the quality and
expectancy of life of HIV-infected individuals [1]. However, in
spite of viral-suppressing drug intervention, immune activation
and loss of regulatory T-cells (T-reg), of CD4
+ T cells, B cells,
central memory CD4
+ and CD8
+ T cells and of immune functions
are only partially reverted by HAART [1–8]. These dysfunctions
are associated with an increased risk of non-AIDS-defining
illnesses, including atherosclerosis, liver and kidney diseases,
tumors and accelerated aging, that are now seen in HIV-treated
disease [3].
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13540To block these effects, novel non virus-targeting interventions,
such as CCR5 antagonists, are being explored in association with
conventional drugs [9,10]. However, this approach appears to be
only partially effective, suggesting that pathogenetic factors that
maintain HIV disease should be targeted for restoring immune
functions.
In this respect, residual virus replication is detected in most
patients receiving HAART, likely originating from viral reservoirs,
including latently infected CD4
+ T cells, monocyte-macrophages,
dendritic cells, NK cells, hematopoietic stem cells, mast cells and
several cell types in the central nervous system [11–21]. This
finding implies that viral gene products are still produced even
under a ‘‘successful’’ therapy. Indeed, multi-spliced transcripts
encoding HIV regulatory proteins are persistently expressed in
viral reservoirs by unintegrated proviral DNA [22,23], and are
detected in resting CD4
+ T cells, monocytes, and hematopoietic
stem cells of HAART-treated individuals in the absence of
detectable viremia [12,13,18,22,24–28]. Thus, HIV regulatory
proteins are produced in latently infected cells [29], and can
contribute to the persistent immune activation, immune system
dysfunction, and disease observed in many HAART recipients
[2,4,5,17,23,30–32].
In particular, production of the Tat protein in virologically-
suppressed individuals is confirmed by evidence of anti-Tat
antibody (Ab) seroconversion and increases of Tat-specific T cell
responses in HAART-treated patients (B. Ensoli et al., unpub-
lished data).
Tat is the transactivator of HIV gene expression, which is
essential for viral replication [33–35] and, therefore, for establish-
ment of infection or virus reactivation [36–39]. Upon virus entry
into cells, Tat is expressed by proviral DNA prior to virus
integration [23], and it is released extracellularly early during
Figure 1. Flow diagram of the study participants. One hundred and forty-four HAART-treated patients were screened for enrollment. Of them,
87 met the inclusion criteria and were randomized on schedule and dose of immunization. This represents all the study population prior to the
protocol amendment. All recruited individuals were included in the safety analysis (n=87). Six subjects discontinued the immunization schedule. Of
them, 5 were evaluated only for safety, since received at least one immunization, and 1 was evaluated also for immunogenicity since received 3
immunizations out of 5 (as indicated in the Protocol S1). A total of 82 individuals completed the 20-weeks period of the study and 68 have completed
the 48-weeks period after the first immunizations.
doi:10.1371/journal.pone.0013540.g001
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secretory pathway similar to that used by bFGF and IL-Ib to exit
cells [40,42,43]. Upon release Tat binds heparan sulphate
proteoglycans of the extracellular-matrix and is detected in tissues
of infected individuals [40,44]. Extracellular Tat exerts activities
on both viral infection and immune activation that are key in
acquisition of infection, as well as for virus reactivation and for
HIV disease maintenance in HAART treated individuals
[23,31,32,38,40,42–51].
By targeting cells expressing RGD-binding integrin receptors
such as dendritic cells, macrophages and activated endothelial cells
via its RGD-binding site, extracellular Tat enters them very
efficiently [44,47,52]. In these cells, Tat activates the proteasome
leading to increased antigen processing and presentation thus
contributing to Th-1 cell activation [48,53,54]. At the same time,
via induction of TNFa, Tat induces the maturation of dendritic
cells toward a Th-1 phenotype, again increasing T cell responses
[31,47,52]. Tat also activates expression of cytokines with key
immunomodulatory effects and/or capable of activating HIV gene
expression [31,45,55–60]. Extracellular Tat also induces HIV co-
receptor expression [61,62] and can activate virus replication,
rescue defective provirus, and facilitate virus transmission to
neighbour cells [40,43,50]. Of note, the Tat protein is detected in
highly purified virions [63], further supporting its key role in virus
transmission and establishment of infection.
Thus, Tat plays key roles any time the virus needs to establish or
to reactivate infection, i.e. at the acquisition of infection or under
HAART-mediated viral suppression, both of which are accompa-
nied by the presence of unintegrated proviral DNA expressing
regulatory gene products and RGD-containing Tat protein
isoforms [64–66].
Consistently with the roles of Tat in HIV pathogenesis, the
presence of anti-Tat immune responses correlates with low or no
progression to AIDS. In fact, when present, cellular and Ab anti-
Tat responses exert protective roles to control virus replication and
to delay disease progression, both in humans and monkeys
[67–72]. Recently, a retrospective analysis on 112 monkeys with
67 vaccinees and 45 controls indicated that vaccination with Tat
has statistically significant protective effects against acquisition of
infection, and, in viremic monkeys, reduces significantly set-point
viral load and CD4
+ T cell decline [73]. Not surprisingly, anti-Tat
Ab are produced by a small fraction (20%) of HIV-infected
individuals in the asymptomatic phase and are lost during
progression [69,71]. In contrast, high Ab titers are produced
against all viral products at all infection stages [74].
With these observations on Tat in mind, and after successful
completion of preclinical [75–77] as well as preventative and
therapeutic phase I studies [78–81] (http://www.hiv1tat-vaccines.
info/), a phase II multicentric open-label clinical trial of
immunization with the active Tat protein (ISS T-002, Clinical-
Trials.gov NCT00751595) was initiated in anti-Tat Ab negative,
HAART-treated and virologically-suppressed individuals. The
primary endpoint of the trial was immunogenicity and the
secondary endpoint was safety evaluation. In addition, the effect
of Tat immunization on the immune activation and dysfunction
seen in treated HIV disease was explored as second-line testing.
A parallel and prospective observational study (ISS OBS T-002,
ClinicalTrials.gov NCT01024556) conducted on HAART-treated
and virologically-suppressed individuals by the same clinical and
laboratory platforms of the trial, and stratified to match the trial
inclusions criteria served for intergroup comparison (data are
shown in Supplementary material).
The open-label design of the phase II trial allowed us to follow
up in a ‘‘real time’’ fashion all incoming data and to fine tune-up
the second-line testing focused at assessing biomarkers of
HAART efficacy. This exploratory testing was then included
also in the observational study (OBS) to verify prospectively the
presence or not of the same modifications found in the
immunized population.
Due to the encouraging results, an ad hoc exploratory interim
analysis was conducted on 87 subjects which completed the
treatment phase. The results indicated that therapeutic immuni-
zation with Tat is safe, immunogenic and reverts biomarkers of
HIV disease that persist under virologically-suppressing antiretro-
viral treatment [1–5]. In addition, greater therapeutic effects were
seen in more immune compromised individuals. After reviewing of
these data by the Investigators, the Data Safety Monitoring Board
(DSMB), the International Advisory Board (IAB), and the
Community Advisory Board (CAB), and in view of the urgency
to improve HIV treatment, an amendment was proposed to and
approved by the Ethical Committees. This amendment extends
the trial to include also more immune compromised individuals
and to expand the total sample size from 128 to 160 volunteers.
Thus, the trial is still continuing and it is now recruiting according
to the broader inclusion criteria (ClinicalTrials.gov NCT0075-
1595; Supporting information).
Table 1. Baseline characteristics of the study participants.
ISS T-002 (n=87)
a
Age (yr)
Mean 6 s.d.
b 4167
Range 26–54
Sex (%)
Male 78.2
Female 21.8
CD4
+ nadir (cells/mL)
Mean 6 s.d. 3526114
Range 252–846
CD4
+ (cells/mL)
Mean 6 s.d. 6936210
Range 425–1490
CD4
+ (%)
Mean 6 s.d. 3467
Range 19–53
HIV RNA (copies/mL) ,50
Time since diagnosis of HIV (yr)
Mean 6 s.d. 966
Range 1–23
Time since HAART initiation (yr)
c
Mean 6 s.d. 664
Range 0–19
Current HAART regimen (%)
Includes PI 25.3
Includes NNRTI 65.5
Includes NRTI 9.2
aNumber of evaluable individuals;
bStandard deviation;
cBased on 76
individuals.
All study participants enrolled prior to the protocol amendment are shown.
doi:10.1371/journal.pone.0013540.t001
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are reported here and they proof the role of Tat in HIV
pathogenesis and disease maintenance under HAART, providing
encouragement for combining Tat immunization with conven-
tional virus-targeting drugs for an improved treatment of HIV
disease.
Methods
The protocol for the ISS T-002 clinical trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1. The protocol for the ISS OBS
T-002 observational study is available as Supporting information;
see Protocol S2.
ISS T-002 trial design, conduction and duration
The study ‘‘A phase II randomized, open label, immunogenicity and safety
trial of the vaccine based on the recombinant biologically active HIV-1 Tat
protein in anti-Tat antibody negative HIV-1 infected HAART treated adult
subjects’’, ISS T-002 (EudraCT No. 20072007200216; Clinical-
Trials.gov NCT00751595) is a randomized, open-label, phase II
multicentric clinical trial directed at evaluating the immunogenic-
ity (primary end-point) and the safety (secondary end-point) of the
HIV-1 Tat protein in HIV-1 infected adult subjects, anti-Tat Ab
negative, of either gender, 18-55 years-old, HAART-treated with
chronic suppressed infection and levels of plasma viremia
,50 copies/mL in the last 6 months prior to screening and
without a history of virologic rebound, with CD4
+ T cell counts
$400 cells/mL and with pre-HAART CD4 nadir .250 cells/mL.
The study was approved by the national regulatory body and by
the Ethics Committees of each clinical center. All subjects signed
the written informed consent prior to enrollment. The trial was
conducted in 10 clinical sites in Italy (Policlinico of Modena,
Modena; Arcispedale S. Anna, Ferrara; Istituti Fiosterapici Ospitalieri
San Gallicano, Rome; Policlinico of Bari, Bari; Ospedale S.M. Goretti
Latina; Fondazione S. Raffaele, Milan; Ospedale S. Maria Annunziata
Florence; Ospedale Luigi Sacco, Milan; Spedali Civili, Brescia;
Ospedale A. di Savoia, Turin). Subjects were randomized, with a
competitive enrolment, to one of the four immunization regimens
represented by 3 or 5 intradermal administrations of Tat at two
doses (7.5 mgo r3 0mg). The study includes 3-weeks screening
period, 8-weeks or 16-weeks treatment period, 40-weeks or 32-
Table 2. Adverse Events (AEs) defined as certainly, probably or possibly related to the study medication.
Incidence and Severity of Treatment-Related AEs by Preferred Term
Tat 7.5 mg
(N=41) Severity
c
Tat 30 mg
(N=46) Severity
c
System Organ Class (SOC) MedDRA Preferred Term n
a n/N
b (%) 1 2 3 n
a n/N
b (%) 1 2 3
Blood and lymphatic system disorders Lymphocytic infiltration 1 2.4 1 0 0 0 0.0 0 0 0
Cardiac disorders Chest Discomfort 1 2.4 0 0 1 0 0.0 0 0 0
Bradycardia 1 2.4 0 1 0 0 0.0 0 0 0
Eye disorders Photophobia 1 2.4 1 0 0 0 0.0 0 0 0
Visual impairment 1 2.4 1 0 0 0 0.0 0 0 0
Conjunctivitis 1 2.4 1 0 0 0 0.0 0 0 0
Gastrointestinal disorders Nausea 0 0.0 0 0 0 1 2.2 1 0 0
General disorders Asthenia 1 2.4 1 0 0 1 2.2 1 0 0
Fatigue 1 2.4 1 0 0 0 0.0 0 0 0
Hyperidrosis 1 2.4 1 0 0 0 0.0 0 0 0
Injection site discomfort 0 0.0 0 0 0 1 2.2 1 0 0
Injection site erythema 0 0.0 0 0 0 1 2.2 1 0 0
Injection Site Irritation 4 9.8 4 0 0 2 4.3 2 0 0
Injection Site Pain 10 24.4 10 0 0 13 28.3 13 0 0
Malaise 1 2.4 1 0 0 0 0.0 0 0 0
Pyrexia 0 0.0 0 0 0 4 8.7 4 0 0
Musculoskeletal and connective tissue disorders Muscular weakness 0 0.0 0 0 0 1 2.2 1 0 0
Nervous System Disorders Agitation 1 2.4 1 0 0 0 0.0 0 0 0
Aphasia 1 2.4 0 0 1 0 0.0 0 0 0
Disturbance in attention 1 2.4 1 0 0 0 0.0 0 0 0
Dysarthria 1 2.4 0 0 1 0 0.0 0 0 0
Headache 3 7.3 3 0 0 1 2.2 1 0 0
Paraesthesia oral 1 2.4 0 0 1 0 0.0 0 0 0
Trigeminal neuralgia 1 2.4 0 1 0 0 0.0 0 0 0
Skin and subcutaneous tissue disorders Erythema 0 0.0 0 0 0 1 2.2 1 0 0
Pruritus generalised 1 2.4 1 0 0 0 0.0 0 0 0
an=number of subjects reporting the events;
b N=number of evaluable subjects (%);
c Severity grade: 1=mild, 2=moderate, 3=severe.
All the study participants prior to the protocol amendment (n=87) have been evaluated for safety. The Medical Dictionary for Regulatory Activities (MedDRA) was used
to classify the adverse events occurred during the study.
doi:10.1371/journal.pone.0013540.t002
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foresees an extended follow-up of 3 years from the first
immunization (Supporting information).
Blood samples from clinical sites were shipped by a certified
courier to the Core Laboratory of Immunology and Virology
(Ospedale S. Gallicano IFO, Rome, Italy) where all the
immunological and virological testing was performed according
to the Standard Operating Procedures (SOP) developed within the
AIDS Vaccine Integrated Program (AVIP) [82], funded within the
FP6 program of the European Community, and implemented in
the corresponding phase I preventative (Clinicaltrials.gov Identi-
fier NCT00529698) and therapeutic (Clinicaltrials.gov Identifier
NCT00505401) clinical trials [78–81].
All safety assessments were performed at the clinical sites
according to the study schedule (see Protocol S1 in Supporting
information). The study was monitored and quality assured by an
accredited Contract Research Organization (CRO). The study
enrolment started on July 2008 and is still open since an
amendment has been approved by the DSMB and Ethical
Committees to include individuals with a more advanced immune
compromission and to expand the sample size from 128 to 160
volunteers (www.clinicaltrials.gov) (Supporting information).
The data shown here refer to the protocol prior to the
amendment (Protocol S1) and include all the pre-amendment
enrolled volunteers (87).
Study Medication
The study medication is the biologically active recombinant Tat
protein administered intradermally in two doses (7.5 mg and
30 mg) according to two regimens (3 or 5 immunizations) at week
0, 4, 8 or 0, 4, 8, 12, 16, respectively. Before administration, the
study medication (Tat 7.5 mg/0.5 mL or Tat 30 mg/0.5 mL) was
thawed, diluted with 1.5 mL of sterile water, swirled gently and
then administered by two intradermal injections into the right and
left deltoid regions of the upper arms.
Study Outcomes
The primary pre-specified outcome of the study (immunoge-
nicity) was measured by the induction, magnitude and persistence
of the humoral immune responses to Tat, and by comparing the
immunogenicity of the 3 or 5 immunization schedule of the two
different vaccine doses (7.5 mga n d3 0mg) at each scheduled time
point (see Protocol S1 in Supporting information). ‘‘Responders’’
were defined as those subjects with at least a positive anti-Tat Ab
response at any given time point after the first immunization.
Cellular immune responses to Tat were a co-primary endpoint.
The anti-Tat humoral immune response was evaluated by
determination and titration of IgM, IgG and IgA anti-Tat Ab in
sera, while the anti-Tat cellular immune response was evaluated
by the assessment of CD4
+ and CD8
+ lymphoproliferative
responses and in vitro IFN-c, IL-4 and IL-2 production in response
to Tat, as detailed below.
The secondary pre-specified outcome of the study (safety) was
assessed by the collection of all adverse events occurred during the
study, including any significant change in haematological
(including coagulation assessment), biochemical (with liver and
kidney functional parameters) and immunological parameters
(including CD4
+, CD8
+, CD3
+ T cells, NK, B cells and mono-
cytes). All the AEs were reported according to the Medical
Dictionary for Regulatory Activities (MedDRA) and classified on
the basis of the drug relationship as well as by the grade of severity.
All the safety data were periodically (every 3 months) evaluated
by the DSMB and Annual Safety reports were submitted to the
Regulatory Bodies at scheduled times, as by regulatory guidelines
(DLgs 211/2003).
Finally, a second-line exploratory testing was performed to
characterize in-depth biochemical and immunological biomarkers
of disease progression used to assess HAART efficacy, including
determination of cellular and biochemical markers of immune
activation, regulatory T cells, cell viability, CD4
+ T cells, CD8
+ T
cells, B cells and NK cells, central and effector memory CD4
+ and
Table 3. Related or unrelated serious adverse events occurred during the ISS T-002 trial.
Volunteer Randomization Description Relationship Severity Action taken Outcome
group to treatment
#13 0 mg, 5 imm. Hepatitis A Unrelated Severe Hospitalization Resolved
Treatment discontinued
#27 . 5 mg, 5 imm. Disarthria and Possible Severe Hospitalization Resolved
Paresthesia Treatment discontinued
of the tongue
#37 . 5 mg, 3 imm. Neurosyphilis Unrelated Mild Hospitalization Ongoing
#43 0 mg, 3 imm. Uterin fibroma Unrelated Severe Medication required Resolved
Treatment discontinued
#53 0 mg, 5 imm. Hodgkin’s Unrelated Severe Medication required Ongoing
lymphoma
#67 . 5 mg, 3 imm. Transaminase Unrelated Moderate Hospitalization Resolved
increase
#73 0 mg, 3 imm. Right occipital Unrelated Severe Medication required Ongoing
lesion
(ischemic event)
All study participants prior to the protocol amendment (n=87) have been evaluated.
doi:10.1371/journal.pone.0013540.t003
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+ T cells as well as cellular responses to HIV Env and to recall
antigens, as detailed below.
All data have been reviewed by the Investigators, the DSMB,
the IAB and the CAB.
Sample size
The primary objective of the trial was to assess the immuno-
genicity of Tat immunization. In particular, ‘‘responders’’ were
defined as subjects with at least a positive anti-Tat Ab response at
any given time point after the first immunization, as indicated in
the Protocol S1 (Supporting information).
To observe a proportion of at least 80% of subjects with Ab
responses to vaccination, taking into account a maximum margin
of error of 7% and a confidence level of 95%, 112 valuable
subjects were found to be required, 28 for each treatment group.
In this hypothesis the width of the confidence interval within each
of the 4 randomization arms is 15%.
With this sample size a difference of at least 35% of the
responders between the two Tat doses with each immunization
schedule (3 or 5 inocula, respectively) is detected as statistically
significant.
Considering a drop-out rate no greater than 10%, the
calculated sample size is 128 subjects, randomized in 4 treatment
groups by 32 subjects each.
Randomization
Since the study design foresees different immunization sched-
ules, subjects were randomized into 4 treatment groups to ensure
unbiased patient allocation.
The Randomization list was generated by the CRO using a
block size of 4, according to a randomization scheme of 1:1:1:1
(RND PLUS 2.10 software).
The randomization assignment was carried out by the CRO via
web. Each clinical site received a block of 4 numbered treatments
(according to the randomization list). A code was assigned at
screening at each subject. The code is constituted by the clinical
trial code (T2) followed by the clinical site number (01 to 10) and
by the progressive patient number within each site. The code was
assigned to each volunteer at screening, irrespectively of enrol-
ment. Once eligibility was established, the clinical staff contacted
the CRO via web to randomize the subject. The drug kit number
to be assigned to the subject was provided via web within the
Figure 2. Anti-Tat humoral immune responses. (A) Percentage of subjects developing anti-Tat IgM (blue bar), IgG (purple bar), IgA (violet bar),
or total anti-Tat Ab (green bar), stratified by Tat dose and treatment groups. Responder frequency up to week 20 among groups was analyzed by the
Cochran-Armitage Trend test (p=0.0117 and p=0.0051 for IgM and IgA, respectively). Tat 7.5 mg, 3x, n=21; Tat 7.5 mg, 5x, n=18; Tat 30 mg, 3x,
n=21; Tat 30 mg, 5x, n=22 subjects, respectively. (B) Percentage of subjects positive for anti-Tat Ab at week 48 (Tat 7.5 mg, 3x, n=20; Tat 7.5 mg, 5x,
n=15; Tat 30 mg, 3x, n=17; Tat 30 mg, 5x, n=16 subjects, respectively). Responder frequency among groups was analyzed as described above
(p=0.0024 and p=0.0048 for IgM and IgG, respectively, p=0.0007 for total Ig). (C) Peak of anti-Tat IgM, IgG or IgA titers (geometric mean and range)
up to 20 weeks after the first immunization from subjects positive for anti-Tat Ab (blue diamond Tat 7.5 mg and red square Tat 30 mg). Anti-Tat IgM:
Tat 7.5 mg, n=14; Tat 30 mg, n=28. Anti-Tat IgG: Tat 7.5 mg, n=26; Tat 30 mg, n=33. Anti-Tat IgA: Tat 7.5 mg, n=7; Tat 30 mg, n=24 subjects,
respectively. (D) Anti-Tat IgM, IgG or IgA titers at 48 weeks after the first immunization from subjects positive for anti-Tat Ab. Anti-Tat IgM: Tat 7.5 mg,
n=6; Tat 30 mg, n=20. Anti-Tat IgG: Tat 7.5 mg, n=8; Tat 30 mg, n=18. Anti-Tat IgA: Tat 7.5 mg, n=5; Tat 30 mg, n=10 subjects, respectively.
doi:10.1371/journal.pone.0013540.g002
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drug kit number was recorded on the e-CRF.
ISS OBS T-002 observational study enrollment and
conduction
The ISS OBS T-002 (ClinicalTrials.gov NCT01024556) is a 5-
years prospective observational study, which started before the
therapeutic trial and is conducted in parallel at the same clinical
centers, and follows the same procedures of the therapeutic trial
ISS T-002 (sample collection and certified transportation,
centralized immune and virologic testing, certified CRO manage-
ment). The primary objective of this study is to prospectively
evaluating the clinical, immunological and virological parameters
to determine the impact of naturally occurring (i.e., not induced by
vaccination) anti-Tat immunity in HIV-infected individuals, of
either gender, $18 years-old, with HAART-suppressed HIV
replication (plasma viremia ,50 copies/mL for 6 months prior to
screening) without a history of virologic rebound and with known
CD4
+ T cell number and nadir. In addition, the study had the
secondary objective of harmonizing the multicentric clinical
Figure 3. Anti-Tat cellular immune responses. (A) Percentage of subjects showing anti-Tat specific production of IFN-c, IL-2 or IL-4, respectively,
measured at baseline (blue bar) and up to week 48 after the first immunization (red bar) and stratified by Tat dose (Tat 7.5 mg, n=35; Tat 30 mg,
n=33 subjects, respectively). (B) Percentage of subjects showing anti-Tat CD4
+ or CD8
+ lymphoproliferative responses measured at baseline and up
to week 48 and stratified by Tat dose (Tat 7.5 mg, n=31; Tat 30 mg, n=31). The analysis was performed using the McNemar’s test: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0013540.g003
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prepare cohorts for trials and to optimize all the operations
required for the therapeutic trial conduction. The study is still
recruiting. To date 127 patients have been enrolled and are being
followed-up, 25 of them are anti-Tat Ab positive and 91 are anti-
Tat Ab negative (Fig. S1). Eighty-eight anti-Tat Ab negative (out
of the 91) are evaluable subjects (Total OBS Subjects), and 32 out
of them meet all the immunological (CD4
+ T cell counts
$400 cells/mL, pre-HAART CD4 nadir .250 cells/mL) and
virological criteria for eligibility in the ISS T-002 clinical trial,
representing therefore the appropriate Reference Group for a
comparative assessment of the results with the trial subjects (Fig.
S1, Table S1). For clarity, data from the observational study are
reported in the Supplementary material section and the protocol is
available in Supporting information (Protocol S2).
Anti-Tat antibodies
Ab were assessed as described [76,79,81,83]. Titers are
expressed as the reciprocal of sample dilution. Ab titers equal or
higher than 25 for IgM and IgA, or 100 for IgG were considered
as positive.
IFN-c, IL-2 and IL-4 Elispot
Elispot was performed as previously described [79–81] using
commercial kits (EL285, EL202, EL204, R&D Systems), with 4
pools of overlapping 15mer-Tat peptides (5 mg/mL each) (UFP
Service, Ferrara, Italy), 2 pools of Env peptides (5 mg/mL each)
(Neosystem), Candida (5 mg/mL) (Nanogen Advanced Diagnos-
tics), or a combination of Cytomegalovirus, Epstein-Barr and
influenza virus (CEF) peptide pool (2 mg/mL each) (Anaspec,
01036–05). PHA, (2 mg/mL) or medium were the positive and the
negative controls, respectively. Tests were considered valid when
Spot Forming Cells (SFC)/well were $100 in positive controls.
IFN-c Elispot was considered positive when SFC/10
6 cells were
$30, and fold-increase over control was $3. The IL-2 and IL-4
Elispot were considered positive when fold-increase was $3.
T cell proliferation
Responses to Tat (1–5 mg/mL) or Tat peptides (2 mg/mL), Env
(5 mg/mL) (Fitzgerald), Candida (5 mg/mL), or CEF peptide pool
(2 mg/mL each) were assessed by CellTrace CFSE Cell Prolifer-
ation kit (Molecular probesTM, Invitrogen), elaborated by ModFit
software (Verity Software House, INC.), and expressed as
Proliferation Index (PI). Fold-increase (FI), calculated as ratio of
Table 4. Tat-specific cellular immune responses in subjects with a positive response after immunization with Tat.
ISS T-002 Tat 7.5 mg
b Tat 30 mg
c
n Baseline Up to week 48 n Baseline Up to week 48
IFN-c
Peak
a (SFC/10
6 cells) 9 30 (10–48) 142 (92–208)** 5 14 (12–16) 50 (42–100)
IL-2
Peak
a (SFC/10
6 cells) 13 8 (2–30) 60 (30–104)* 12 9 (3–19) 29 (20–38)**
IL-4
Peak
a (SFC/10
6 cells) 5 6 (0–10) 40 (36–46) 5 2 (0–2) 44 (24–58)
CD4 Proliferation
Peak
a (fold increase) 23 1.9 (1.4–2.9) 2.5 (2.1–4.5)** 24 2.2 (1.6–3.0) 3.8 (2.3–5.5)**
CD8 Proliferation
Peak
a (fold increase) 20 2.1 (1.4–3.4) 4.0 (2.6–8.5)** 25 2.7 (1.6–6.5) 5.4 (2.5–8.2)**
The median intensity, with interquartile range of peak of responses, is shown for subjects with at least a positive cellular response at any given time point after the first
immunization and up to week 48. Pre-post vaccination median change was evaluated by the Wilcoxon signed-rank test. IFN-c, IL-2, IL-4 production by PBMC and CD4
+
or CD8
+ lymphoproliferative responses were measured at baseline and up to week 48 after the first immunization. Results are stratified by Tat doses, (7.5 and 30 mg). n
indicates the number of responders.
aMedian (interquartile range) of peak of responses, weeks 8, 12, 20, 48.
bTotal subject tested for cytokines: 35; for proliferation: 31.
cTotal subjects tested for proliferation: 33; for proliferation: 31.
*P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0013540.t004
Table 5. Immune activation markers and T-reg at baseline in
study participants.
ISS T-002 n Mean ± s.e.
CD38
+HLA-DR
2 on CD8
+ T cells (%) 38 31.562.0
HLA-DR
+CD38
2 on CD8
+ T cells (%) 38 5.560.8
CD38
+HLA-DR
+ on CD8
+ T cells (%) 38 6.060.7
CD38
+ HLA-DR
2 on CD4
+ T cells (%) 37 49.762.2
HLA-DR
+CD38
2 on CD4
+ T cells (%) 37 4.560.5
CD38
+HLA-DR
+ on CD4
+T cells (%) 37 3.860.5
b2-microglobulin (mg/L) 77 1.760.1
Neopterin (nmol/L) 77 7.561.0
Total IgM (mg/dL) 77 7765
Total IgG (mg/dL) 77 1025629
Total IgA (mg/dL) 77 196611
CD25
+ on CD4
+ T cells (%) 66 8.660.3
FOXP3
+ on CD4
+CD25
+ T cells (%) 60 31.261.4
CD25
+FOXP3
+ on CD4
+ T cells (%) 60 2.760.2
CD25
+FOXP3
+ on CD4
+ T cells (cells/mL) 59 19.4611.7
Mean values (6 standard error) of phenotypic and biochemical immune
activation markers and T-regs of the study participants at baseline. n indicates
the number of individuals tested for each parameter.
doi:10.1371/journal.pone.0013540.t005
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when was $2.
Peripheral Blood Mononuclear Cell (PBMC) viability and
lymphocyte subsets
Cell viability was determined by Trypan Blue Dye Exclusion
using the Vi-CELLTM XR Counter (Beckman Coulter) [84,85].
Phenotyping was performed with BD Multitest 6-color TBNK
reagent with BD Truecount tubes, (BD Biosciences). Samples were
processed by FACSCanto flow cytometer (BD Biosciences) and data
analyzed by FACSCanto clinical software. CD4
+ T cell counts were
also performed in parallel at each clinical center, and results were
highly consistent with those generated by the Core lab.
Immune activation markers and T-reg
Whole blood was stained with anti-CD8 FITC/CD38 PE/CD3
PerCP/HLA-DR APC (MultiTEST
TM BD Biosciences) plus anti-
CD4 APC-Cy7 Ab (BD Pharmingen). Collective quadrant gates,
based on HLA-DR and CD38 expression on CD4
+ or CD8
+ T
cells, were established.
Neopterin, b2-microglobulin and total immunoglobulins (Ig)
were determined as described [86].
For CD25
+ and T-reg, PBMCs were stained with anti-human
APC-Cy7-labeled CD4, APC-labeled CD25 (BD Biosciences) and
PE-labeled FOXP3 Ab (Bioscience, USA). Gating was performed
on CD4
+ and CD4
- for CD25 expression on total T cells, and on
CD4
+ T cells for CD25/FOXP3 doubly-positive cells, and then on
CD4/CD25 for FOXP3
+ lymphocytes.
Naı ¨ve, central and effector memory CD4
+ or CD8
+ T cells
PBMC were stained with anti-human CD3 (PerCP), CD4
(APC-Cy7), CD8 (APC), CD45RA (FITC), CD62L (PE) Ab
(MultiTEST
TM BD Biosciences), analyzed by FACSCanto flow
cytometer (BD Biosciences) with the FlowJo (Tree Star, Ashland,
OR) software.
T cell subsets were identified by hierarchical gating (morpho-
logical, on CD3
+, and then on CD4
+ or CD8
+ T cells). Collective
quadrant gates based on CD45RA and CD62L expression on
CD3
+/CD4
+ or CD3
+/CD8
+ T cells identified naı ¨ve (CD45RA+/
CD62L+), central memory (CD45RA-/CD62L+, Tcm), effector
memory (CD45RA-/CD62L-, Temro), and terminally-differenti-
ated effector memory (CD45RA+/CD62L-, Temra) subsets.
HIV-1 viral load
HIV-l RNA was determined with COBAS AmpliPrep/COBAS
TaqMan HIV-1 Test, version 2.0, (Roche Diagnostics) [84,87].
Statistical methods
The percentage of ‘‘responders’’ was estimated both for total
vaccinees and for each randomization group with a 95%
confidence interval.
Cochran-Armitage Trend test was used to compare frequencies
of humoral responses. McNemar’s test was used to compare pre-
post immunization frequencies of cellular responses within
treatment groups. Wilcoxon signed-rank test was applied to
evaluate increase of cellular responses intensity. Student’s t-test for
paired data was used to assess the mean changes from baseline of
Figure 4. Expression of activation markers on CD8
+ T cells after Tat immunization. Changes from baseline of CD8
+ T cells (gating on CD8
+
T cells) expressing (A) CD38, (B) HLA-DR, or (C) both CD38 and HLA-DR. Results are shown according to Tat dose and time after the first
immunization. Data are presented as the mean % changes (6 standard error) at week 8, 12, 20 and 48. Blue bars: Tat 7.5 mg, n=17 up to week 20 and
n=12 at week 48; red bars: Tat 30 mg, n=21 up to week 20, n=16 at week 48, respectively. The t-Test for paired data was used for the analyses:
*p,0.05, **p,0.01. (D) Correlation between CD38
+/CD8
+ T cells (%) and anti-Tat IgA antibody titers (Multivariate regression model for repeated
measures). Blue diamond: Tat 7.5 mg, n=39; red square: Tat 30 mg, n=43, respectively.
doi:10.1371/journal.pone.0013540.g004
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+ T cells after Tat immunization. Changes from baseline of CD4
+ T cells (gating on CD4
+
T cells) expressing (A) CD38, (B) HLA-DR, or (C) both CD38 and HLA-DR. Results are shown according to Tat dose and time after the first
immunization. Data are presented as the mean % changes (6 standard error) at week 8, 12, 20 and 48. Blue bars: Tat 7.5 mg, n=17 up to week 20 and
n=12 at week 48; red bars: Tat 30 mg, n=20 up to week 20, n=15 at week 48, respectively; The t-Test for paired data was used for the analyses:
*p,0.05, **p,0.01.
doi:10.1371/journal.pone.0013540.g005
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controlling normality assumption of variables distribution (Sa-
phiro-wilk test). Multivariate regression model for repeated
measures, stratified by Tat dose, was applied to CD38
+/CD8
+ T
cells (%), including anti-Tat Ab titers, cell viability and CD25
+
FOXP3
+ expression on CD4
+ lymphocytes as explicative factors.
The same model was applied on CD38
+/CD8
+ T cells (%) to all
immunized subjects, to assess the potential relationships with the
anti-Tat Ab titers (IgM, IgG, IgA), CD8
+ central memory (%) and
anti-Tat induced cytokines (IFN-c, IL-2 and IL-4).
Since phase II studies are usually descriptive and are not
designed to quantify treatment effects, the statistical analyses were
not focused to determine differences in term of efficacy among
three or more treatment groups and no adjustments were used for
multiple comparisons. Therefore, exploratory analyses were
applied to many variables to investigate the potential effect of
the Tat immunization on the immunological status of vaccinees.
All statistical tests were carried out at a two-sided 5%
significance level. Analyses and data processing were performed
using SASH software (SAS Institute, Cary, NC, USA).
Figure 6. Production of b2-microglobulin and neopterin after Tat immunization. Changes from baseline, according to Tat dose, of (A) b2-
microglobulin serumlevels (mg/L) and (B) Neopterin (nmol/L). Blue bars: Tat 7.5 mg; red bars: Tat30 mg. Data are presentedas the mean changes (6standard
error) at 4, 16 and 24 weeks (Tat 7.5 mg, n=37, Tat 30 mg, n=40 subjects, respectively). The t-Test for paired data was used for the analyses: **p,0.01.
doi:10.1371/journal.pone.0013540.g006
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PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e13540Figure 7. Production of total Ig after Tat immunization. Total IgM (A), IgG (B) and IgA (C) serum levels (mg/dL) are shown. Blue bars: Tat
7.5 mg, n=37; red bars: Tat 30 mg, n=40. Data are presented as the mean changes (6 standard error). The t-Test for paired data was used for the
analyses: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0013540.g007
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Study participants
Study participants were randomized by immunization schedule (3
or 5 times monthly) and Tat doses (7.5 or 30 mg) (Fig. 1 and Table 1
and Methods). The results refer to the full pre-amendment trial
population (n=87). Sixty-eight trial participants had also a 48-weeks
of follow-up.
Eighty-eight HAART-treated anti-Tat Ab negative and virolog-
ically-suppressed individuals (for at last 6 months and without a
history of virological rebound) with a known number of CD4
+ Tc e l l s
and CD4 T cell nadir, were enrolled in the prospective observational
study (ISS OBS T-002, ClinicalTrials.gov NCT00751595). The
results of this study served for intergroup comparison. In particular,
32 of these subjects fully matched the baseline characteristics of the
immunized patients and were, therefore, considered as the Reference
Group (Fig. S1, Table S1 and Methods). However, since no major
differences were seen between the Reference Group and the full OBS
population (Total OBS Subjects), results from both these groups are
reported (Supplementary material).
Safety Data of therapeutic immunization with the
biologically active Tat protein
Safety was assessed in all trial (n=87) volunteers by monitoring
local and systemic adverse events (AEs) as well as hematological,
biochemical and immunological laboratory parameters as per-
formed previously in phase I trials [79–81]. Since in immunized
subjects no differences in the incidence of adverse events were
detected between the number of inocula (3 or 5) with the same Tat
dose, the results were stratified by Tat dosages.
No relevant AEs occurred during the study, and most of them
were expected both in frequency and type for HIV-infected
subjects (Table 2). In particular 51/87 subjects (59%) experienced
AEs during the study. Out of them, 26/87 (30%) presented a
certain, probable or possible relationship to the study treatment and
were not related to the Tat dosage. These events were mostly local,
related to the injection site and mild in severity (Table 2).
Seven serious adverse events (SAE) occurred after Tat
immunization, but only one was indicated as possibly related to
the study treatment (Table 3).
Based on the first and second year Annual Safety Report and on
the periodic meetings and reports, the DSMB of the ISS T-002
deliberatedthat theimmunization withTat issafeand welltolerated.
Therapeutic immunization with Tat induces specific
humoral and cellular immune responses in HAART-
treated individuals
Responders were defined by the induction of anti-Tat Ab. Total
responders were 79% (95%C.I. 70–88%), with a higher frequency
Figure 8. CD25 and FOXP3 expression on CD4
+ T cells after Tat immunization. (A) Changes from baseline of CD4
+ lymphocytes expressing
CD25 are shown according to Tat dose and time after the first immunization (Tat 7.5 mg, n=32 up to week 20 and n=24 at week 48; Tat 30 mg, n=34
up to week 20 and n=28 at week 48, respectively). (B) Changes from baseline of the percentage of CD4
+CD25
+ lymphocytes expressing FOXP3
+ (Tat
7.5 mg, n=31 up to week 20 and n=23 at week 48; Tat 30 mg, n=29 up to week 20 and n=28 at week 48, respectively). (C) Changes from baseline of
the percentage of CD4
+ T cells expressing CD25
+FOXP3
+ (Tat 7.5 mg, n=31 up to week 20 and n=23 at week 48; Tat 30 mg, n=29 up to week 20 and
n=24 at week 48). (D) Changes from baseline of the absolute number of CD4
+ lymphocytes expressing CD25
+ FOXP3
+ (Tat 7.5 mg, n=30 up to week
20 and n=20 at week 48; Tat 30 mg, n=29 up to week 20 and n=22 at week 48, respectively). Blue bars: Tat 7.5 mg; red bars: Tat 30 mg. Data are
presented as the mean changes (6 standard error) evaluated at 8, 12, 20 and 48 weeks after the first immunization. The t-Test for paired data was
used for the analyses: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0013540.g008
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Tat 7.5 mg dose (72%; 95%C.I. 58–86%). After stratification by
the randomization groups, responders were 76% (95%C.I. 58–
94%) at 7.5 mg, 3 inocula, and 67% (95%C.I. 45–88%) after 5
inocula, respectively. At the 30 mg Tat dose responders were 86%
(95%C.I. 71–100%) after 3 inocula and 86% (95%C.I. 72–100%)
after 5 inocula, respectively.
The 30 mg dose was, therefore, more potent at inducing anti-Tat
Ab and atmaintaininglong-termhumoral responseswith littleorno
differences between the 3 or 5 inoculation regimens (Fig. 2 A–B).
Specifically, during the immunization phase (up to week 20) the
30 mg Tat dose was the most effective at inducing anti-Tat IgM and
IgA subclasses (p=0.0117 and p=0.0051, respectively) (Fig. 2A).
This Tat dose was also the most effective at inducing a durable Ab
response (p=0.0007), which was still present at approximately 1
year post-immunization (48 weeks), for both IgM and IgG
subclasses (p=0.0024 and p=0.0048, respectively) (Fig. 2B). In
contrast, peak Ab titers did not significantly differ between doses
and only slightly decreased at 48 weeks (Fig. 2 C, D).
Both Tat doses induced specific cellular responses (Fig. 3 A–B
and Table 4). A cumulative analysis of the T cell responses (up to
48 weeks after immunization) indicated an increase in the
percentage of responders for production of IL-2 (p=0.0348 and
p=0.0039 at Tat 7.5 or 30 mg, respectively) and, to a lesser extent,
IFN-c and IL-4, as well as of Tat-specific CD4
+ (p=0.0013 at Tat
7.5 mg) and CD8
+ T cell proliferation. No relevant differences
were observed between 3 or 5 immunizations.
Further, increased peak values were detected for both cytokines
and CD4
+ and CD8
+ T cell proliferation in response to Tat,
which reached significance with Tat at 7.5 mg for IFN-c
(p=0.0078), and IL-2 (p=0.0327), and at Tat 30 mg for IL-2
(p=0.0005), and with both Tat doses for CD4
+ and CD8
+ T cell
proliferation (p,0.001) (Table 4).
Immunization with Tat downregulates phenotypic and
biochemical markers of immune activation and increases
regulatory T cells
To further investigate the effect of immunization with Tat, key
biomarkers of AIDS pathogenesis and progression used to evaluate
HAART efficacy were determined as second-line exploratory
testing. These included phenotypic (CD38, HLA-DR) and
biochemical (serum b2-microglobulin, neopterin and total immu-
noglobulins) immune activation markers. In addition, T-reg
lymphocytes, that are markedly reduced in HIV-infected individ-
uals even under HAART, were monitored since these cells are key
for controlling immune activation and both the generation and
termination of adaptive immune responses. Baseline values of
these parameters were determined at study entry (Table 5). Since
no differences were detected in immunized subjects between the
number of inocula (3 or 5) with the same Tat dose, results were
stratified by Tat dosage.
CD38 and HLA-DR expression
Downregulation of CD38 expression was observed on CD8
+ T
cells from subjects immunized with both Tat doses, and was more
pronounced and persistent at Tat 30 mg, reaching statistical
significance at week 20 (p=0.0436) to decline thereafter (week 48)
(Fig. 4 A and Table 5). At the same time, a significant increase of
HLA-DR expression on CD8
+ T cells, either alone or with CD38,
was also observed in subjects immunized with both Tat doses with
a peak at week 12 (Tat 7.5 mg, p=0.0071; Tat 30 mg, p=0.0001),
remaining significantly higher at week 48 (Tat 7.5 mg, p=0.0039;
Tat 30 mg, p=0.0023) (Fig. 4 B, C). The most evident effects were
again observed with Tat 30 mg, for which the average frequency of
CD38
+/HLA-DR
+ doubly-positive CD8
+ T lymphocytes re-
mained significantly higher up to week 48 (p=0.0010).
Of note, a longitudinal analysis showed a significant correlation
of CD38 downregulation on CD8
+ T cells with increasing anti-Tat
IgA titers following the Tat 30 mg immunization
[log10 IgA: b=-6.0% (95% CI 210.5%; 21.5%) p=0.0087].
The modulation of the expression of these markers was somewhat
opposite on CD4
+ T cells (Fig. 5 A–C). In particular, the percentage
of CD38 singly-positive CD4
+ T cells was increased in immunized
subjects with both Tat doses and up to week 48, remaining significant
for Tat 30 mg (p=0.0038), whereas HLA-DR expression had little
changes after immunization. In contrast, the frequencies of CD38
+/
HLA-DR
+ doubly-positive CD4
+ T lymphocytes were reduced in
immunized subjects at all time points and at both Tat doses.
Biochemical markers of immune activation
The down-regulation of cellular markers of immune activation
following Tat immunization was associated with an early decrease
(week 4) in the serum levels of b2-microglobulin (p,0.0001) (Fig. 6
A), and neopterin (Fig. 6 B).
Different changes were observed for total Ig according to the
isotype (Fig. 7 A–C). In particular, only total IgG were significantly
decreased early (week 4) post-immunization and at both Tat doses
(Tat 7.5 mg, p=0.0258; Tat 30 mg, p=0.0111), remaining
thereafter below baseline levels only for Tat 30 mg.
CD25 expression and T-regulatory Cells
After Tat immunization, the percentage of total CD25
+/CD4
+ T
cells markedly diminished returning to baseline values at week 48.
This reduction was greater with Tat 30 mg, reaching a nadir at 12
Table 6. Inverse correlation between baseline values and
changes after Tat immunization of immune activation markers
and T-regs.
ISS T-002 n
Pearson
correlation p-value
coefficient
CD38
+HLA-DR
2 on CD8
+ T cells (%) 38 r=20.5 0.0005
CD38
2HLA-DR
+ on CD8
+ T cells (%) 38 r=20.5 0.0023
CD38
+HLA-DR
+ on CD8
+ T cells (%) 38 r=20.4 0.0190
CD38
+ HLA-DR
2 on CD4
+ T cells (%) 37 r=20.3 0.0623
HLA-DR
+CD38
2 on CD4
+ T cells (%) 37 r=20.7 ,0.0001
CD38
+HLA-DR
+ on CD4
+T cells (%) 37 r=20.8 ,0.0001
b2-microglobulin (mg/L) 77 r=20.3 0.0017
Neopterin (nmol/L) 77 r=20.9 ,0.0001
Total IgM (mg/dL) 77 r=20.1 0.5371
Total IgG (mg/dL) 77 r=20.4 0.0001
Total IgA (mg/dL) 77 r=0.0 0.7519
CD25
+ on CD4
+ T cells (%) 66 r=20.5 ,0.0001
FOXP3
+ on CD4
+CD25
+ T cells (%) 60 r=20.5 0.0001
CD25
+FOXP3
+ on CD4
+ T cells (%) 60 r=20.3 0.0171
The relationship between baseline values and changes at week 20 or week 24
for all immunized subjects was evaluated by the Pearson correlation coefficient
(r) after cumulating both Tat doses. n indicates the number of individuals
evaluated for each parameter.
doi:10.1371/journal.pone.0013540.t006
HAART Intensification by Tat
PLoS ONE | www.plosone.org 14 November 2010 | Volume 5 | Issue 11 | e13540HAART Intensification by Tat
PLoS ONE | www.plosone.org 15 November 2010 | Volume 5 | Issue 11 | e13540weeks post-immunization and remaining significant at week 20
(p=0.0351) (Fig. 8 A),beforereturning to baselinelevelsat week 48.
This finding was paralleled by a significant and persistent
increase of the percentage of FOXP3 expression in the CD4
+/
CD25
+ T cell subset as well as of the percentage and absolute
number of CD4
+/CD25
+/FOXP3
+ T-reg, which had a significant
and progressive increase at both Tat doses and persisted up to
week 48 (T-regs % at Tat 7.5 mg, p=0.0146, at Tat 30 mg,
p=0.0002; T-regs number at Tat 7.5 mg, p=0.0090, at Tat
30 mg, p=0.0018) (Fig. 8 C, D).
The changes of immune activation markers and T-reg observed
upon immunization were significantly and inversely related to
baseline values (Table 6), in that the reduction in immune
activation markers was more pronounced in subjects with the
highest values at baseline. Conversely, the largest increase in
T-reg cell number was seen in individuals with the lowest baseline
values.
Immunization with Tat increases PBMC viability and the
number of CD4
+ T cells and B cells
PBMC viability in vitro is reduced in HIV infection [88]. In
contrast, progressive and significant increments of cell viability
were seen in PBMC early after immunization (since week 8) with
both Tat doses and particularly with Tat 30 mg. Cell viability
continued to increase up to week 48 with both Tat doses
(p,0.0001, Fig. 9 A).
The CD4
+ T cell number increased after Tat immunization, at
all time-points and for both Tat doses (Fig. 9 B), reaching statistical
significance with the 7.5 mg Tat dose at week 8 (57 cells/mL,
p=0.0206), week 16 (69 cells/mL, p=0.0188), week 20 (68 cells/
mL, p=0.0418), week 24 (48 cells/mL, p=0.045) and week 48
(54 cells/mL, p=0.0806), and for the 30 mg Tat dose at week 8
(59 cells/mL, p=0.0181) and week 16 (52 cells/mL, p=0.0388).
Similarly, the B cell number also increased upon immunization
with both Tat doses and at all time-points (Fig. 9 C), reaching
statistical significance with Tat 7.5 mg at week 8 (46 cells/mL,
p=0.0250), week 20 (28 cells/mL, p=0.0368) and week 48
(66 cells/mL, p=0.0261), as well as with Tat 30 mg at week 8
(26 cells/mL, p=0.0241) and week 12 (25 cells/mL, p=0.0200).
Immunization with Tat increases the percentage of CD4
+
T cells and B cells and reduces the percentage of CD8
+
and NK cells independently from the type of HAART
regimen
The determination of the percentage of lymphocyte subsets
confirmed the increase of CD4
+ T cells and B cells observed for
the absolute values, showing significant increases of CD4
+ T cells,
particularly at week 20 (1%, p=0.0218) and 48 (2%, p=0.0010),
as well as significant increases of B cells at all time-points starting
from week 8 (1%, p,0.01) (Fig. 10 A). In contrast, the percentage
of NK and CD8
+ T cells were significantly reduced at week 20
(21%, p=0.0288) and 48 (21.4%, p=0.0217), respectively.
These effects were observed with both Tat doses (Fig. 10 B, C).
As a consequence, the CD4/CD8 ratio progressively increased
in immunized subjects with the most evident effects at week 20 and
48 from the first immunization, and, particularly, for the 30 mg
Tat dose (week 20, p=0.0117; week 48, p=0.0011).
Stratification of these results according to the type of HAART
regimen (NNRTI-based or PI-based) indicated that Tat immuni-
zation can overcome the differences seen with different drugs
regimens on lymphocyte subsets, suggesting that the effects of Tat
immunization are independent from the type of drugs combina-
tion (Fig. 11 A, B).
Immunization with Tat increases central memory and
reduces terminally- differentiated effector memory
(Temra) CD4
+ and CD8
+ T cells
Since reduction of central memory T cells (Tcm) with a
concomitant increase of effector memory cells (Tem) is commonly
observed in HIV infection and this unbalance is only partially
restored under effective HAART [5], these T cell subsets were
evaluated upon immunization with Tat. The percentage of central
(CD45RA
2/CD62L
+) and, to a lesser extent, effector (CD45RA
2/
CD62L
+, Temro) memory CD4
+ and CD8
+ T cells increased upon
Tat immunization (Fig. 12).
For CD4
+ T cells, these findings were concomitant with a
reduction of both terminally-differentiated Tem (CD45RA+/
CD62L
2, Temra) and naı ¨ve (CD45RA
+/CD62L
+) T cells
(Fig. 12 A). These changes were evident 8 weeks after the first
immunization, peaked at week 12 (Tcm, p=0.0176; Temra,
p=0.0080; naı ¨ve T cells, p=0.0018) and declined thereafter but
did not return to baseline values (Fig. 12 A).
For CD8
+ T cells the earliest and most prominent changes were
observed for Temra, which were significantly reduced at all time-
points post-immunization, reaching a nadir at week 48 (Fig. 12 B).
In contrast, the increase in Tcm was less pronounced and slower
for CD8
+ cells as compared to CD4
+ cells, reaching statistical
significance only at week 20 (p,0.0001). As for CD4
+ T cells, also
the percentage of CD8
+ Temro increased after immunization,
reaching statistical significance at week 12 (p=0.0378). Unlike the
CD4
+ counterpart, the CD8
+ naı ¨ve subset remained largely
unaffected by the treatment (Fig. 12 B).
Immunization with Tat increases cellular responses to
HIV-Env and to recall antigens
To verify whether the effects of Tat-immunization were
accompanied by changes in adaptive immunity against heterolo-
gous antigens, T cell responses against HIV-Env, Candida, or CEF
antigens were determined by monitoring Th1 and Th2 cytokine
production and CD4
+ and CD8
+ T cell proliferation. An increase in
both the percentage of responders and the intensity of responseswas
found in subjects immunized with both Tat doses (Fig. 13 A–F and
Table 7–9). In particular, statistically significant increases in the
percentage of responders were detected against Env for IFN-c (Tat
7.5 mg, p=0.0348; Tat 30 mg, p=0.0005), and against Candida for
IL-2 (Tat 7.5 mg, p=0.0076; Tat 30 mg, p=0.0027) and IL-4 (Tat
7.5 mg, p=0.0114; Tat 30 mg, p=0.0184). Statistically significant
increases of CD4
+ and CD8
+ T cell proliferation were detected
against Env (for CD4
+ at Tat 7.5 mg, p=0.0114, at Tat 30 mg,
p=0.0455; for CD8
+ at Tat 7.5 mg, p=0.0016), and Candida (for
CD4
+atTat7.5 mg,p=0.0253,atTat30 mg,p=0.0010;forCD8
+
Figure 9. Evaluation of PBMC viability, CD4
+ T cell and B cell counts after Tat immunization. (A) Changes from baseline of in vitro PBMC
viability, stratified by Tat dose. Blue bars: Tat 7.5 mg, n=35 up to week 20 and n=32 at week 48; red bars: Tat 30 mg, n=40 up to week 20 and n=33
at week 48, respectively. (B) Changes from baseline of CD4
+ T cells/mL (data from clinical sites), stratified by Tat dose. Blue bars: Tat 7.5 mg, n=39 up
to week 24 and n=30 at week 48; red bars Tat 30 mg, n=43 up to week 24 and n=34 at week 48. (C) Changes from baseline of B cells/mL, stratified
by Tat dose. Blue bars: Tat 7.5 mg, n=38 up to week 20 and n=30 at week 48; red bars Tat 30 mg, n=40 up to week 20 and n=30 at week 48,
respectively. The t-Test for paired data was used for the analyses: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0013540.g009
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response to CEF was already present in most subjects with no
differences after immunization (Fig. 13 E). In contrast, CD4
+ and
CD8
+ T cell proliferation to CEF were very low at baseline and
increased after immunization particularly upon vaccination with
30 mg of Tat for both CD4
+ (p=0.0114) and CD8
+ (p=0.0067) T
cell subsets (Fig. 13 F).
The intensity (peak values) of both cytokine production and
proliferative responses to Env as well as to recall antigens including
CEF were significantly increased after immunization (p,0.05,
Table 7–9).
Correlations of Tat immunization with changes in the T
cell compartments
A multivariate regression analysis was used to assess the
presence of potential correlations among the different parameters
investigated after therapeutic immunization. A statistically signif-
icant inverse correlation was found between the percentage of
CD38
+/CD8
+ T cells with anti-Tat IgA titers (p=0.0309), CD8
+
Tcm lymphocytes (p=0.0316), and with IL-2 production in
response to Tat (p=0.0235) (Fig. 14 A–C), suggesting a direct
relationship between the induction of anti-Tat specific IL-2
producing cells and increasing anti-Tat IgA titers with the
expansion of CD8
+ Tcm and the reduction of activated CD8
+
effector T cells.
Comparison of Tat-immunized subjects with patients
enrolled in the observational Study (ISS OBS T-002)
Although the effects and the limits of a successful HAART are
well known [89], an intergroup comparison between trial subjects
and those enrolled in the parallel ISS OBS T-002 study was made
to better evaluate the effect of Tat immunization on virologically-
suppressed patients (see Methods section, Protocol S2 and
Supplementary material). Out of 88 evaluable patients (Total
OBS Subjects) enrolled in this study (see Methods section), 32
subjects fully matched the baseline characteristics of the trial
participants (Fig. S1 and Table S1). This group was considered as
the Reference Group, and comparison of immunized subjects was
made with both this Reference Group and the Total OBS Subjects
for all assessed parameters (Table 10, 11). The baseline values of
the OBS subjects for activation markers and T-reg lymphocytes
were determined at study entry (Table S2).
A decrease of CD38 and HLA-DR expression on CD8
+ T cells
either alone or in combination was observed during the follow up
for both Total OBS Subjects and Reference Group (Fig. S2, A–F).
These results are in sharp contrast with the upregulation of HLA–
DR expression, alone or combined with CD38, observed on CD8
+
T cells from immunized subjects (Fig. 4 A–C).
The modulation of CD38 and HLA–DR expression on CD4
+ T
cells of OBS subjects was similar to that observed on CD8
+ T cells
(Fig. S2 G–L). Thus, the pattern of expression of these two
activation markers differed from what observed in the immunized
subjects in whom an opposite and statistically significant
upregulation of CD38 expression on CD4
+ T cells was observed
(Fig. 5 A–C).
The biochemical markers of immune activation were scarcely
modified in the Reference Group throughout follow-up (Fig. S3
A–E). Specifically, b2-microglobulin showed an early increase and
then a gradual but slight decrease, while neopterin was slightly but
persistently increased respect to baseline values (Fig. S3 A, B). In
contrast, both these activation markers were reduced at most time-
points in immunized patients (Fig. 6 A, B).
Total IgM, IgG and IgA remained substantially stable in OBS
subjects for most of the follow up (Fig. S3 C–E), whereas a
significant reduction of total IgG was recorded early after
immunization in trial subjects (Fig. 7 A–C).
Overall, in the OBS patients the percentage of total CD25
+/
CD4
+ T cells was stable, with an increase at week 48 (Fig. S4 A and
Fig. S5 A). Conversely, the percentage of CD4
+/CD25
+ T cells
expressing FOXP3 gradually decreased in the Total OBS Subjects
(Fig. S4B) aswell asintheReferenceGroup (Fig.S5 B). Inaddition,
a decrease was observed in the percentage and absolute number of
the CD4
+/CD25
+/FOXP3
+ T-reg subset in the Total OBS
Subjects (Fig. S4 C, D), whereas the decline was less pronounced
in the Reference Group (Fig. S5 C, D). The opposite was observed
inthe patients immunized with Tat, inwhichanoverallreductionof
CD25 expression and a concomitant and persistent statistically
significant increase of T-reg were detected (Fig. 8 A–D).
Cell viability increased at late time-points (36 and 48 weeks)
both in the Total OBS Subjects and in the Reference Groups (Fig.
S6 A, B), as opposed to immunized individuals in whom a
significant and steady increase of cell viability was detected as early
as 8 weeks after the first immunization, particularly with the 30 mg
Tat dose (Fig. 9 A).
No significant changes of the CD4
+ T cell number were
detected in individuals from either the Total OBS (Fig. S6 C) or
the Reference Group (Fig. S6 D). This is in contrast with the
statistically significant and persistent increase of CD4
+ T cells
observed in the subjects immunized with Tat (Fig. 9 B).
Further, a progressive loss of B cells was observed in both OBS
groups (Fig. S6 E, F), a finding in striking contrast with the early,
durable and statistically significant increments of B cells observed
in the Tat immunized subjects (Fig. 9 C).
These differences between the trial and OBS groups were also
reflected by the percentage of lymphocyte subsets. In fact, as
compared to baseline levels, in the OBS study were detected a
moderate increase of the CD4
+ T cell percentage, an overall
stability (Total OBS Subjects) or decrease (Reference Group) of
the B cell subset (Fig. S7 A, B), a stable (Total OBS Subjects) or
further increased (Reference Group) percentage of CD8
+ T cells,
and a substantial stability of the NK subset. Again, opposite trends
were apparent in immunized patients in whom a persistent
increase of the percentage of CD4
+ T and B cells and a progressive
decrease of CD8
+ T cells and NK cells were recorded, irrespective
of the type of HAART regimen (Fig. 11 A, B). In this regard,
analysis of OBS subjects after stratification by NNRTI-based or
PI-based treatment showed a different profile of lymphocytes
subsets, particularly for B cells (Fig. S7 C–E), indicating a positive
effect of Tat immunization in HAART intensification indepen-
dently from the type of drugs combination.
The percentage of central memory (CD45RA
2/CD62L
+)
CD4
+ (Fig. S8 A, C) and CD8
+ (Fig. S8 B, D) T cells was stable
or moderately increased, though not significantly, at week 24 both
for the Total OBS and Reference Group, as opposed to the more
pronounced increments that were recorded in immunized subjects
(Fig. 12 A, B). In the effector memory CD4
+ and CD8
+
Figure 10. Evaluation of the percentage of CD4
+, CD8
+, NK and B cells in all Tat-immunized subjects and after stratification by Tat
dose. (A) Changes from baseline of CD4
+, CD8
+, NK and B cells (percentage) for all immunized subjects (n=78 up to week 20, n=60 at week 48). (B,
C) Changes from baseline of CD4
+, CD8+, NK and B cells (percentage), stratified by Tat doses. (B) Tat 7.5 mg, n=38 up to week 20 and n=30 at week
48; (C) Tat 30 mg, n=40 up to week 20 and n=30 at week 48, respectively. The t-Test for paired data was used for the analyses: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0013540.g010
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+, CD8
+, NK and B cells in all Tat-immunized subjects after stratification by HAART
regimens. Changes from baseline of CD4
+, CD8
+, NK and B cells (percentage) from all immunized patients are shown for NNRTI-based (A) and PI-
based (B) treatments. NNRTI-based: n=51 up to week 20 and n=41 at week 48; PI-based: n=19 up to week 20 and n=12 at week 48, respectively.
The t-Test for paired data was used for the analyses: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0013540.g011
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2/CD45RA+)
subset and a concomitant increase of the Temro (CD62L
2/
CD45RA-) subpopulation were observed at week 24 in the OBS
subjects (Fig. S8, A–D), while similar but earlier and more
pronounced changes were evident in the immunized patients
(Fig. 12 A, B). Finally, individuals from both the trial and the OBS
study experienced a decline of naı ¨ve (CD45RA
+/CD62L
+) CD4
+
and CD8
+ T cells (Fig. 12 and Fig. S8 A–D).
The cumulative assessment of the cellular immune responses to
Tat (up to 48 weeks of follow up) revealed an increase of the
percentage of responders in terms of both specific cytokines
production, except for IL-2 production in the Reference Group,
and particularly of CD8
+ T cell proliferation in both the Total
OBS Subjects and the Reference Group (Fig. S9 A, B and Fig. S10
A, B). These changes were also quantitative, in that an increase in
the peak values of cytokine production and CD8
+ T cell
proliferation was also detected for both groups (Table S3). In
contrast, greater and statistically significant increments were seen
for IL-2 production and CD4
+ T cell proliferation in subjects
immunized with Tat.
The percentage of responders and the intensity of responses
were also evaluated for HIV-Env, Candida and CEF antigens in
both the Total OBS Subjects and in the Reference Group (Fig. S9
C–H, Fig. S10 C–H and Tables S4, S5, S6). No changes were
Figure 12. Effect of Tat immunization on naı ¨ve, central and effector memory CD4
+ and CD8
+ T cells. Percentage of naı ¨ve (CD45RA
+/
CD62L
+), effector RA
+ (CD45RA
+/CD62L
2, Temra) or RA- (CD45RA
2/CD62L
2, Temro) and central memory (CD45RA
2/CD62L
+, Tcm) CD4
+ (A) or CD8
+
(B) T cells at baseline and at week 8, 12, 20 and 48 after the first immunization for subjects immunized with both Tat doses (n=18 up to week 20 and
n=10 at week 48). Asterisk indicates significant changes from baseline. The t-Test for paired data was used for the analyses: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0013540.g012
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PLoS ONE | www.plosone.org 20 November 2010 | Volume 5 | Issue 11 | e13540Figure 13. Cellular immune responses against Env or recall antigens after Tat immunization. Percentage of responders at baseline (blue
bar) and up to week 48 (red bar) are stratified by Tat dose. Percentage of subjects showing (A) anti-Env production of IFN-c, IL-2 and IL-4 (Tat 7.5 mg,
n=31; Tat 30 mg, n=29) and (B) CD4
+ or CD8
+ lymphoproliferative responses (Tat 7.5 mg, n=31; Tat 30 mg, n=30); (C) anti-Candida cytokines
production (Tat 7.5 mg, n=32; Tat 30 mg, n=29), and (D) CD4
+ or CD8
+ lymphoproliferative responses (Tat 7.5 mg, n=31; Tat 30 mg, n=29); (E) anti-
CEF production of IFN-c, IL-2 and IL-4 (Tat 7.5 mg, n=34; Tat 30 mg, n=32), and (F) CD4
+ or CD8
+ lymphoproliferative responses (Tat 7.5 mg, n=31;
Tat 30 mg, n=29). The analysis was performed using the McNemar’s test: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0013540.g013
Table 7. Cellular immune responses against Env after Tat immunization.
ISS T-002 Tat 7.5 mg
b Tat 30 mg
c
n Baseline Up to week 48 n Baseline Up to week 48
IFN-c
Peak
a (SFC/10
6 cells) 19 44 (0–394) 382 (86–834)** 18 53 (12–226) 236 (86–920)**
IL-2
Peak
a (SFC/10
6 cells) 19 52 (18–76) 94 (52–166)** 20 26 (14–49) 49 (38–95)**
IL-4
Peak
a (SFC/10
6 cells) 20 52 (16–122) 137 (44–464)** 18 24 (11–64) 80 (28–132)
CD4 Proliferation
Peak
a (fold increase) 15 1.5 (0.8–3.8) 2.4 (2.1–4.7)* 21 1.5 (0.8–2.8) 2.9 (2.2–4.5)**
CD8 Proliferation
Peak
a (fold increase) 20 2.0 (1.1–4.1) 3.1 (2.5–7.2)* 18 2.7 (1.1–5.0) 5.6 (3.9–7.0)*
IFN-c, IL-2, IL-4 production by PBMC, and CD4 or CD8 lymphoproliferative responses to Env were measured at baseline and up to week 48 after the first immunization,
respectively. Results are stratified by Tat doses, (7.5 and 30 mg). n indicates the number of responders for cytokines production and CD4 or CD8 T cell proliferation,
respectively. The median intensity with interquartile range of peak of responses is shown. Pre-post vaccination median change was evaluated by Wilcoxon signed-rank
test.
aMedian (interquartile range) of peak of responses, weeks 8, 12, 20, 48.
bTotal subject tested for cytokines: 31; for proliferation: 31.
cTotal subjects tested for cytokines: 29; for proliferation: 30.
*P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0013540.t007
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responders for CD4
+ and CD8
+ T cell proliferation against Env
increased in the follow-up period in both the Total OBS Subjects
(Fig. S9 D) and in the Reference Group (Fig. S10 D). In Total OBS
Subjects, the percentage of responders to Candida increased for IL-
4 productionas well as for CD4
+ and CD8
+ T cell proliferation (Fig.
S9E,F).SimilartrendswereobservedfortheReferenceGroup(Fig.
S10 E, F). Increases in the percentage of responders to CEF were
found for all cytokines, while no relevant changes were observed for
lymphoproliferative responses for both Total OBS Subjects and the
Reference Group (Fig. S9 G, H and Fig. S10 G, H).
In addition, in both Total OBS Subjects and in the Reference
Group, the intensity (peak values) of proliferative responses but not
cytokine production to Env were increased, whereas for recall
antigens both cytokine production and T cell proliferation were
increased (Tables S4, S5, S6).
Table 8. Cellular immune responses against Candida after Tat immunization.
ISS T-002 Tat 7.5 mg
b Tat 30 mg
c
n Baseline Up to week 48 n Baseline Up to week 48
IFN-c
Peak
a (SFC/10
6 cells) 6 40 (0–70) 69 (46–150) 5 82 (82–118) 132 (82–266)
IL-2
Peak
a (SFC/10
6 cells) 28 98 (28–181) 175 (101–346)** 28 73 (48–111) 133 (93–259)**
IL-4
Peak
a (SFC/10
6 cells) 13 8 (0–34) 66 (36–124)** 16 6 (0–13) 60 (34–110)**
CD4 Proliferation
Peak
a (fold increase) 20 1.6 (1.2–2.0) 4.8 (2.3–6.1)** 24 1.7 (1.2–2.8) 4.1 (2.8–4.9)**
CD8 Proliferation
Peak
a (fold increase) 19 1.8 (1.3–4.6) 4.9 (2.8–9.9)** 19 1.5 (1.2–3.8) 5.7 (3.9–8.9)**
IFN-c, IL-2, IL-4 production by PBMC, and CD4 or CD8 lymphoproliferative responses to Candida were measured at baseline and up to week 48 after the first
immunization, respectively. Results are stratified by Tat doses, (7.5 and 30 mg). n indicates the number of responders for cytokines production and CD4 or CD8 T cell
proliferation, respectively. The median intensity with interquartile range of peak of responses is shown. Pre-post vaccination median change was evaluated by Wilcoxon
signed-rank test.
aMedian (interquartile range) of peak of responses, weeks 8, 12, 20, 48.
bTotal subject tested for cytokines: 32; for proliferation: 29.
cTotal subjects tested for cytokines: 29; for proliferation: 29.
**P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0013540.t008
Table 9. Cellular immune responses against CEF after Tat immunization.
ISS T-002 Tat 7.5 mg
b Tat 30 mg
c
n Baseline Up to week 48 n Baseline Up to week 48
IFN-c
Peak
a (SFC/10
6 cells) 32 713 (332–1144) 1244 (750–1684)** 32 1054 (326–1659) 1754 (1064–3947)**
IL-2
Peak
a (SFC/10
6 cells) 34 270 (152–500) 525 (372–638)** 31 266 (142–752) 706 (496–1108)**
IL-4
Peak
a (SFC/10
6 cells) 29 298 (140–736) 728 (312–1132)** 29 504 (148–660) 678 (518–986)**
CD4 Proliferation
Peak
a (fold increase) 4 0.9 (0.8–1.2) 4.2 (3.4–4.9) 9 0.7 (0.7–1.1) 2.8 (2.6–3.0)**
CD8 Proliferation
Peak
a (fold increase) 5 2.3 (1.6–2.7) 2.9 (2.0–3.2) 10 1.0 (0.7–1.2) 3.4 (2.2–4.8)**
IFN-c, IL-2, IL-4 production by PBMC, and CD4 or CD8 lymphoproliferative responses to CEF were measured at baseline and up to week 48 after the first immunization,
respectively. Results are stratified by Tat doses, (7.5 and 30 mg). n indicates the number of responders for cytokines production and CD4 or CD8 T cell proliferation,
respectively. The median intensity with interquartile range of peak of responses is shown. Pre-post vaccination median change was evaluated by Wilcoxon signed-rank
test.
aMedian (interquartile range) of peak of responses, weeks 8, 12, 20, 48.
bTotal subject tested for cytokines: 34; for proliferation: 31.
cTotal subjects tested for cytokines: 32; for proliferation: 29.
**P,0.01.
doi:10.1371/journal.pone.0013540.t009
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jects there was an increase of cytokine production to Env
and Candida and of CD4
+ and CD8
+ proliferation to CEF
(Fig. 13 B, D, F).
Discussion
HAART represents a major virus-targeting intervention against
HIV [1]. However, in spite of its success at suppressing HIV
Figure 14. Correlation of the reduction of the percentage of CD38
+/CD8
+ T cells with the increase of anti-Tat IgA antibody titers,
CD8
+ T central memory and anti-Tat specific IL-2 production after Tat immunization. Multivariate regression model for repeated measures
was applied to CD38
+/CD8
+ T cells (%), including as explicative factors anti-Tat antibody titers (IgM, IgG, IgA), CD8
+ central memory (%) and anti-Tat
IFN-c, IL-2 and IL-4 cytokines, for immunized subjects (n=70).
doi:10.1371/journal.pone.0013540.g014
Table 10. Qualitative comparison of the results of the ISS T-
002 Clinical Trial and the ISS OBS T-002 Observational Study
up to 48 weeks of follow-up: activation markers, T-regs, cell
viability and lymphocyte phenotype.
ISS
T-002
a
Reference
Group
b
Total OBS
Subjects
c
Activation markers
Phenotypic (%)
CD38
+HLA-DR
2 on CD8
+ T cells 2 (*) 22 (*)
HLA-DR
+CD38
2 on CD8
+ T cells + (*) 2 (*) 2 (*)
CD38
+HLA-DR
+ on CD8
+ T cells + (*) 22 (*)
CD38
+ HLA-DR
2 on CD4
+ T cells + (*) 2 (*) 2 (*)
HLA-DR
+CD38
2 on CD4
+ T cells +/22 (*) 2 (*)
CD38
+HLA-DR
+ on CD4
+T cells 2 (*) 22 (*)
CD25
+ on CD4
+ T cells 2 (*) ++
Biochemical
b2-microglobulin (mg/L) 2 (*) +/2 n.d.
Neopterin (nmol/L) 2 + n.d.
Total IgM (mg/dL) +/2 + n.d.
Total IgG (mg/dL) 2 (*) + n.d.
Total IgA (mg/dL) + (*) + n.d.
T-regs
FOXP3
+ on CD4
+CD25
+ T cells (%) + (*) 2 (*) 2 (*)
CD25
+FOXP3
+ on CD4
+ T cells (%) + (*) 22
CD25
+FOXP3
+ on CD4
+ T cells
(cells/mL)
+ (*) 22 (*)
Cell viability (%) + (*) + (*) + (*)
Lymphocyte cell counts
(cells/mL)
CD4
+ T cell counts + (*) +/2 +
B cell counts + (*) 22
Lymphocyte Phenotype (%)
CD4
+ T cell + (*) ++
CD8
+ T cell 2 (*) + 2
NK 2 (*) +/2 =
B + (*) 2 +/2
CD4/CD8 ratio + (*) ++
aSubjects enrolled in the clinical trial;
bsubjects enrolled in the OBS study with
the same characteristics at baseline of the trial patients;
c all evaluable subjects
enrolled in the OBS study. Shown are the qualitative changes from baseline of
the different study populations for all evaluated parameters. +, increase; 2,
decrease; +/2, fluctuations (higher and lower levels as compared to baseline at
different time points); = stable; (*), statistically significant in at least one time
point; n.d., not done.
doi:10.1371/journal.pone.0013540.t010
Table 11. Qualitative comparison of the results of the ISS
T-002 and the ISS OBS T-002 up to 48 weeks: central and
effector memory T cell phenotype and cellular immune
responses.
ISS
T-002
a
Reference
Group
b
Total OBS
Subjects
c
T cell phenotype (%)
CD4
+ naı ¨ve 2 (*) +/22
CD4
+ Tcm + (*) +/2 +
CD4
+ Temro ++ +
CD4
+ Temra 2 (*) +/2 +/2
CD8
+ naı ¨ve +/22 +/2
CD8
+ Tcm + (*) +/2 +
CD8
+ Temro + (*) ++
CD8
+ Temra 2 (*) +/2 +/2
Anti-Tat (% responders)
IFN-c production ++ + (*)
IL-2 production + (*)= + (*)
IL-4 production ++ (*) +
CD4
+ proliferation + (*) ++
CD8
+ proliferation ++ (*) + (*)
Anti-Env (% responders)
IFN-c production + (*) ++
IL-2 production + 22
IL-4 production + ==
CD4
+ proliferation + (*) ++ (*)
CD8
+ proliferation + (*) ++ (*)
Anti-Candida
(% responders)
IFN-c production = = +
IL-2 production + (*) 22
IL-4 production + (*) ++ (*)
CD4
+ proliferation + (*) ++ (*)
CD8
+ proliferation + (*) ++ (*)
Anti-CEF (% responders)
IFN-c production = + (*) + (*)
IL-2 production = ++ (*)
IL-4 production = + (*) + (*)
CD4
+ proliferation + (*) ++
CD8
+ proliferation + (*) ++
aSubjects enrolled in the clinical trial;
bsubjects enrolled in the OBS study with
the same characteristics at baseline of the trial patients;
c all evaluable subjects
enrolled in the OBS study. +, increase; 2, decrease; +/2, fluctuations (higher
and lower levels as compared to baseline at different time points); = stable;
(*), statistically significant in at least one time point.
doi:10.1371/journal.pone.0013540.t011
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activation, and revert the immune dysregulation seen in treated
individuals [1–8,19]. Since Tat is persistently expressed in cell
reservoirs also under HAART and has important effects on the
virus and on the immune system, we hypothesized that Tat was a
key factor for disease maintenance in drug-treated individuals.
Here we show that therapeutic immunization with Tat further
reduces the immune activation still present under HAART [1–
8,19], and found also here in OBS subjects. In particular, Tat-
immunized individuals, particularly at the 30 mg dose, experienced
a significant reduction of CD38
+/CD8
+ T cells, which was
inversely related to the anti-Tat IgA titers, central memory CD8
+
T cells, and IL-2 production in response to Tat.
The decrease of CD38
+/CD8
+ T cells observed after immuni-
zation was associated with upregulation of HLA-DR expression on
CD8
+ T cells, either alone or in association with CD38, and with an
increase of CD38 expression on CD4
+ T cells. The pattern of the
expression of HLA-DR, either alone or in association with CD38,
on CD8
+ T cells in response to immunization was opposite to what
was observed in OBS subjects and it is consistent with that induced
in healthy individuals by other vaccinations [90]. Notably, CD8
+ T
cells expressing HLA-DR and CD38 have been reported to possess
optimal antiviral functionality [91,92], whereas expression of CD38
on CD4
+ T cells has been associated with reduced susceptibility to
productive HIV infection in vitro [93] and in lymph nodes [94].
Further, although co-expression of DR and CD38 on CD8
+ T
cells has been extensively reported to be associated with immune
activation in HIV progression [95], it is also found in immature
and rapidly cycling T cells [96–99]. This suggests that co-
expression of DR and CD38 may also result from restoration of
homeostatic mechanisms upon therapeutic vaccination with Tat.
Such a scenario is consistent with the increase of CD4
+ and CD8
+
central memory T cells and with the recovery of T cell responses
to HIV and recall antigens, which were observed in vaccinated
individuals. It is therefore tempting to speculate that Tat
immunization reduces the HIV-driven immune dysregulation
and associated anergy, and promotes restoration of proper and
effective immune responses. This may explain the apparently
paradoxical increment of doubly positive (CD38
+/DR
+) activated
CD8
+ T cells despite the concomitant reduction of the other
soluble and cellular inflammation and immune activation markers,
including CD38
+/DR
+ CD4
+ T cells, and the increase of both T-
regs and central memory CD8
+ T cells.
In particular, the frequency and number of T-reg lymphocytes,
which are known to suppress immune activation [100], were stably
increased upon Tat immunization, as observed in elite controllers
[101]. In contrast, they are progressively reduced in HIV-infected
individuals, even under successful HAART [102], as observed also
here in OBS subjects.
The increase of T-reg and the reduction of immune activation
were associated with stable increases of the percentage and
absolute numbers of both CD4
+ T cells and B lymphocytes, and
with the reduction of the percentage of CD8
+ T cells and NK
lymphocytes. As a result the CD4/CD8 T cell ratio progressively
increased. Such a pattern of T and B cell ‘‘repopulation’’ differs
markedly from that reported to occur during HAART [8] and
observed here in the OBS group.
Of note, although differences were observed in the percentage
of lymphocyte subsets with different HAART regimens (NNRTI-
based versus PI-based) in the OBS subjects, Tat immunization had
the same effects independently from the type of therapy,
suggesting that Tat can intensify different HAART regimens.
In such a scenario, the increment or de novo appearance of
cellular adaptive immune responses against HIV Env or to recall
antigens suggests that restoration of key immune parameters takes
place upon Tat immunization. In fact, these results were
associated with increases in CD4
+ and CD8
+ central memory
and functional effector memory T cells [103,104], and with a
reduction of terminally-differentiated, and functionally exhausted,
effector counterparts. This is different from the trend seen in HIV-
treated disease (and also observed in OBS), where central
memory CD4
+ and CD8
+ T cell subsets are incompletely restored
and effector memory T cells remain persistently increased
(Table 10, 11) [5].
Except for the reduction of CD38 on CD8
+ T cells and CD25
on CD4
+ T cells, the effects of vaccination were long-lived since
they were still present or even increased after 48 weeks from the
first immunization.
The data indicate that immunization with Tat acts in synergy
with HAART to help restoring immune homeostasis. Indeed, the
therapeutic effects of Tat immunization were more pronounced in
the patients that were more immune dysregulated at baseline.
The extended follow-up of the vaccinees will provide informa-
tion on the need or timing of vaccine boosting.
Supporting Information
Figure S1 Flow diagram of ISS OBS T-002 study participants.
One hundred and twenty-seven subjects were recruited in the
observational study ISS OBS T-002. Among them, 25 individuals
were anti-Tat Ab positive and 91 anti-Tat Ab negative,
respectively. Evaluable subjects were constituted by 88 anti-Tat
Ab negative (Total OBS Subjects) and 32 Reference Group
subjects, respectively. The Total OBS Subjects included anti-Tat
Ab negative volunteers of either gender, $18 years old, under
successful HAART (chronic suppression of HIV infection with a
plasma viremia ,50 copies/ml in the last 6 months and without a
history of virologic rebound), a known nadir level of CD4+ T cells
and CD4+ T cell number at study entry. The Reference Group
included subjects having at baseline the same characteristics of
volunteers enrolled in the ISS T-002 clinical trial: anti-Tat Ab
negative (18–55 years of age), HAART-treated with chronic
suppressed HIV infection, with levels of plasma viremia ,50 cop-
ies/ml in the last 6 months prior to the screening and without a
history of virologic rebound, CD4+ T cell counts $400 cells/mL
and pre-HAART CD4 nadir .250 cells/mL.
Found at: doi:10.1371/journal.pone.0013540.s001 (2.39 MB TIF)
Figure S2 Expression of activation markers on CD8+ and CD4+
T cells in subjects of ISS OBS T-002. Changes from baseline of
CD8+ T cells (gating on CD8+ cells) expressing (A, B) CD38, (C, D)
HLA-DR, or (E, F) both CD38 and HLA-DR in the Total Subjects
(A, C, E) and in the Reference Group (B, D, F), respectively. Data
are presented as the mean % changes (6standard error) at week 12,
24 and 36. Blue bars: Total Subjects n=16 at week 12, n=6 at
week 24 and n=6 at week 36; light violet bar: Reference Group,
n=6 at week 12, n=3 at week 24. The t-Test for paired data was
used for the analyses: *p,0.05, **p,0.01. Total Subjects:
CD38+HLA-DR- at week 24, p=0.0121; HLA-DR+CD38- at
week 12, p=0.0019; HLA-DR+CD38+ at week 12, p=0.0019.
Reference Group: HLA-DR+CD38- at week 12, p=0.0256.
Changes from baseline of CD4+ T cells (gating on CD4+ cells)
expressing (G, H) CD38, (I, J) HLA-DR, or (K, L) both CD38 and
HLA-DR in the Total Subjects (G, I, K) and in Reference Group
(H, J, L), respectively. Data are presented as the mean % changes
(6standard error) at week 12, 24 and 36. Blue bars: Total Subjects
n=16 at week 12, n=6 at week 24 and n=6 at week 36; light violet
bar: Reference Group, n=6 at week 12, n=3 at week 24. Total
Subjects: CD38+HLA-DR- at week 24, p=0.0048; HLA-
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HLA-DR+CD38+ at week 12, p=0.0139. Reference Group:
CD38+ HLA-DR- at week 24, p=0.0239; HLA-DR+CD38- at
week 12, p=0.0060.
Found at: doi:10.1371/journal.pone.0013540.s002 (2.08 MB TIF)
Figure S3 Production of b2-microglobulin, neopterin and total
Ig in subjects of the Reference Group of ISS OBS T-002. Changes
from baseline of (A) b2-microglobulin serum levels (mg/L), (B)
Neopterin (nmol/L), Total (C) IgM, (D) IgG and (E) IgA serum
levels (mg/dL), respectively. Data are presented as the mean
changes (6 standard error) at 12, 24 and 36 weeks (n=30 at week
12; n=19 at week 24; n=10 at week 36).
Found at: doi:10.1371/journal.pone.0013540.s003 (1.62 MB TIF)
Figure S4 CD25 and FOXP3 expression on CD4+ T cells in
Total Subjects of ISS OBS T-002. (A) Changes from baseline of
CD4+ lymphocytes expressing CD25 are shown for Total Subjects
(n=34 at week 12; n=10 at week 24; n=8 at week 36 and n=8
at week 48). (B) Changes from baseline of the percentage of
CD4+CD25+ lymphocytes expressing FOXP3+ in Total Subjects
(n=31 at w12; n=10 at week 24; n=8 at week 36 and n=8 at
week 48). (C) Changes from baseline of the percentage of CD4+ T
cells expressing CD25+FOXP3+ in Total Subjects (n=31 at
week12; n=10 at week 24; n=8 at week 36 and n=8 at week 48).
(D) Changes from baseline of the absolute number of CD4+
lymphocytes expressing CD25+FOXP3+ in Total Subjects (n=25
at week 12; n=6 at week 24; n=2 at week 36 and n=7 at week
48). Data are presented as the mean changes (6 standard error).
The t-Test for paired data was used for the analyses: *p,0.05,
**p,0.01. CD4+CD25+ lymphocytes expressing FOXP3+ at
week 36, p=0.0220; at week 48, p=0.0017. CD4+/CD25+/
FOXP3+ T-reg number at week 36, p=0.0467.
Found at: doi:10.1371/journal.pone.0013540.s004 (1.72 MB TIF)
Figure S5 CD25 and FOXP3 expression on CD4+ Tc e l l si n
subjects of the Reference Group of ISS OBS T-002 study. (A)
Changes from baseline of CD4+ lymphocytes expressing CD25 are
shown in subjects of the Reference Group (n=20 at week 12; n=8 at
week 24; n=4 at week 36 and n=4 at week 48). (B) Changes from
baseline of the percentage of CD4+CD25+ lymphocytes expressing
FOXP3+ in subjects of the Reference Group (n=19 at week 12;
n=8 at week 24; n=4 at week 36 and n=4 at week 48). (C) Changes
from baseline of the percentage of CD4+ T cells expressing
CD25+FOXP3+ in subjects of the Reference Group (n=19 at week
1 2 ;n =8a tw e e k2 4 ;n = 4a tw e e k3 6a n dn = 4a tw e e k4 8 ) .( D )
Changes from baseline of the absolute number of CD4+ lymphocytes
expressing CD25+FOXP3+ in subjects of the Reference Group
( n=1 5a tw e e k1 2 ;n=5a tw e e k2 4a n dn=4a tw e e k4 8 ) .D a t aa r e
presented as the mean changes (6 standard error). The t-Test for
paired data was used for the analyses: *p,0.05. CD4+CD25+
lymphocytes expressing FOXP3+ at week 48, p=0.0290.
Found at: doi:10.1371/journal.pone.0013540.s005 (1.81 MB TIF)
Figure S6 Evaluation of PBMC viability, CD4+ T cell and B cell
counts in subjects of ISS OBS. Changes from baseline of in vitro
PBMC viability in Total Subjects (A) and the Reference Group
(B); n=88 at week 12; n=62 at week 24; n=46 at week 36 and
n=30 at week 48 for the Total Subjects; n=32 at week 12; n=20
at week 24; n=11 at week 36 and n=6 at week 48 for the
Reference Group. The t-Test for paired data was used for the
analyses: **p,0.01. Total Subjects: at 36 and 48 weeks,
p,0.0001; Reference Group: at week 36, p=0.0003. Changes
from baseline of CD4+ T cells/ml (data from clinical sites) for
Total Subjects (C) and the Reference Group subjects (D); n=76 at
week 12; n=54 at week 24; n=37 at week 36 and n=25 at week
48 for the Total Subjects; n=29 at week 12; n=19 at week 24;
n=10 at week 36 and n=5 at week 48 for subjects of the
Reference Group. Changes from baseline of B cells/mL, for Total
Subjects (E) and the Reference Group subjects (F), n=73 at week
12; n=20 at week 24; n=10 at week 36 for the Total Subjects;
n=27 at week 12; n=8 at week 24; n=3 at week 36 for subjects
of the Reference Group.
Found at: doi:10.1371/journal.pone.0013540.s006 (1.99 MB TIF)
Figure S7 Evaluation of the percentage of CD4+, CD8+,N K
and B cells in subjects of ISS OBS T-002 prior or after
stratification by HAART regimen. Changes from baseline of
CD4+, CD8+, NK and B cells (percentage) for Total Subjects (A)
and Reference Group subjects (B); n=73 at week 12; n=20 at
week 24; n=10 at week 36 for Total Subjects; n=27 at week 12;
n=8 at week 24; n=3 at week 36 for subjects of the Reference
Group. Changes from baseline of CD4+, CD8+, NK and B cells
(percentage) for NNRTI-based (C, D) in Total Subjects (C) and in
the Reference Group subjects (D), respectively, and for PI-based
(E) in Total Subjects. NNRTI-based: n=43 at week 12, n=10 at
week 24, n=6 at week 36 for Total Subjects, and n=16 at week
12, n=4 at week 24, n=3 at week 36 for the Reference Group.
PI-based: n=25 at week 12, n=6 at week 24, n=3 at week 36 for
Total Subjects. The t-Test for paired data was used for the
analyses: *p,0.05. Total Subjects, PI-based: CD8+ T cells at week
24, p=0.0339; B cells at week 36, p=0.0291.
Found at: doi:10.1371/journal.pone.0013540.s007 (1.94 MB TIF)
Figure S8 Characterization of naı ¨ve, central and effector
memory CD4+ and CD8+ T cells in Total Subjects and in the
Reference Group of ISS OBS T-002. Percentage of naı ¨ve
(CD45RA+/CD62L+), effector RA+ (CD45RA+/CD62L-,
Temra) or RA- (CD45RA-/CD62L-, Temro) and central memory
(CD45RA-/CD62L+, Tcm) CD4+ (A) or CD8+ (B) T cells for
total OBS subjects at baseline and at week 12 and 24 (n=6 at
week 0; n=6 at week 12, n=2 at week 24), and for CD4+ (C) or
CD8+ (D) T cells for the Reference Group at baseline and at week
12 and 24 (n=5 at week 0; n=5 at week 12, n=2 at week 24).
Found at: doi:10.1371/journal.pone.0013540.s008 (2.36 MB TIF)
Figure S9 Cellular immune responses against Tat, Env or recall
antigens in Total Subjects of ISS OBS T-002. Percentage of
responders at baseline (green bar) and up to week 48 (orange bar).
(A) Percentage of subjects (n=87) showing anti-Tat production of
IFN-c, IL-2 and IL-4, and (B) percentage of subjects (n=67)
showing anti-Tat CD4+ or CD8+ lymphoproliferative responses.
(C) Percentage of subjects (n=72) showing anti-Env production of
IFN-c, IL-2 and IL-4, and (D) percentage of subjects (n=64)
showing anti-Env CD4+ or CD8+ lymphoproliferative responses.
(E) Percentage of subjects (n=74) showing anti-Candida cytokines
production, and (F) percentage of subjects (n=64) showing anti-
Candida CD4+ or CD8+ lymphoproliferative responses. (G)
Percentage of subjects (n=78) showing anti-CEF production of
IFN-c, IL-2 and IL-4, and (H) percentage of subjects (n=64)
showing anti-CEF CD4+ or CD8+ lymphoproliferative responses.
The McNemar’s test was used for the analyses: *p,0.05,
**p,0.01. Anti-Tat response: IFN-c, p=0.0270; IL-2,
p=0.0411; CD8+ proliferation, p=0.0017. Anti-Env response:
CD4+ proliferation, p=0.0184; CD8+ proliferation, p=0.0007.
Anti-Candida response: IL-4, p=0.0003; CD4+ proliferation,
p=0.0158; CD8+ proliferation, p=0.0411. Anti-CEF response:
IFN-c,p=0.0016; IL-2, p=0.0008; IL-4, p,0.0001.
Found at: doi:10.1371/journal.pone.0013540.s009 (2.71 MB TIF)
Figure S10 Cellular immune responses against Tat, Env or
recall antigens in the Reference Group of ISS OBS T-002.
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PLoS ONE | www.plosone.org 26 November 2010 | Volume 5 | Issue 11 | e13540Percentage of responders at baseline (green bar) and up to week 48
(orange bar). (A) Percentage of subjects (n=31) showing IFN-c,
IL-2 and IL-4 production against Tat, and (B) percentage of
subjects (n=26) showing anti-Tat CD4+ or CD8+ lymphoprolif-
erative responses. (C) Percentage of subjects (n=29) showing anti-
Env production of IFN-c, IL-2 and IL-4, and (D) percentage of
subjects (n=23) showing anti-Env CD4+ or CD8+ lymphoprolif-
erative responses. (E) Percentage of subjects (n=29) showing anti-
Candida production of IFN-c, IL-2 and IL-4, and (F) percentage
of subjects (n=23) showing anti-Candida CD4+ or CD8+
lymphoproliferative responses. (G) Percentage of subjects (n=28)
showing anti-CEF production of IFN-c, IL-2 and IL-4, and (H)
percentage of subjects (n=23) showing anti-CEF CD4+ or CD8+
lymphoproliferative responses. The McNemar’s test was used for
the analyses: *p,0.05, **p,0.01. Anti-Tat response: IL-4,
p=0.0339; CD8+ proliferation, p=0.0348. Anti-CEF response:
IFN-c, p=0.0253; IL-4, p=0.0339.
Found at: doi:10.1371/journal.pone.0013540.s010 (1.37 MB TIF)
Table S1 Baseline characteristics of study participants in ISS
OBS T-002 for the Total Subjects and the Reference Group.
Found at: doi:10.1371/journal.pone.0013540.s011 (0.04 MB
DOC)
Table S2 Immune activation markers and T-regs at baseline in
subjects of ISS OBS T-002.
Found at: doi:10.1371/journal.pone.0013540.s012 (0.04 MB
DOC)
Table S3 Tat-specific cellular immune responses in subjects of
ISS OBS T-002.
Found at: doi:10.1371/journal.pone.0013540.s013 (0.04 MB
DOC)
Table S4 Cellular immune responses against Env in subjects of
ISS OBS T-002.
Found at: doi:10.1371/journal.pone.0013540.s014 (0.04 MB
DOC)
Table S5 Cellular immune responses against Candida in
subjects of ISS OBS T-002.
Found at: doi:10.1371/journal.pone.0013540.s015 (0.04 MB
DOC)
Table S6 Cellular immune responses against CEF in subjects of
ISS OBS T-002.
Found at: doi:10.1371/journal.pone.0013540.s016 (0.04 MB
DOC)
Protocol S1 Trial Protocol.
Found at: doi:10.1371/journal.pone.0013540.s017 (0.89 MB
PDF)
Protocol S2 ISS OBS T-002 Protocol.
Found at: doi:10.1371/journal.pone.0013540.s018 (0.15 MB
PDF)
Checklist S1 CONSORT Checklist.
Found at: doi:10.1371/journal.pone.0013540.s019 (0.23 MB
DOC)
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